About Nuclear receptor subfamily 2 group F member 6
Nuclear receptor subfamily 2 group F member 6 (NR2F6) is a protein
from Homo sapiens identified by UniProt accession
P10588, 404 residues long.
MolForge cross-references it against 0 known binders and
94 disease associations.
Target properties
| Protein name | Nuclear receptor subfamily 2 group F member 6 |
| UniProt accession | P10588 |
| Gene | NR2F6 |
| Organism | Homo sapiens |
| Length | 404 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (94)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- sex hormone-binding globulin measurement · score 0.42
- testosterone measurement · score 0.40
- IGF-1 measurement · score 0.27
- mean platelet volume · score 0.12
- neoplasm · score 0.11
- low density lipoprotein cholesterol measurement · score 0.09
- hepatocellular carcinoma · score 0.08
- melanoma · score 0.08
- head and neck squamous cell carcinoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P10588-F1 | alphafold | PREDICTED | 77.34 | — |
Amino-acid sequence (404 residues)
MAMVTGGWGG PGGDTNGVDK AGGYPRAAED DSASPPGAAS DAEPGDEERP GLQVDCVVCG DKSSGKHYGV FTCEGCKSFF KRSIRRNLSY TCRSNRDCQI DQHHRNQCQY CRLKKCFRVG MRKEAVQRGR IPHSLPGAVA ASSGSPPGSA LAAVASGGDL FPGQPVSELI AQLLRAEPYP AAAGRFGAGG GAAGAVLGID NVCELAARLL FSTVEWARHA PFFPELPVAD QVALLRLSWS ELFVLNAAQA ALPLHTAPLL AAAGLHAAPM AAERAVAFMD QVRAFQEQVD KLGRLQVDSA EYGCLKAIAL FTPDACGLSD PAHVESLQEK AQVALTEYVR AQYPSQPQRF GRLLLRLPAL RAVPASLISQ LFFMRLVGKT PIETLIRDML LSGSTFNWPY GSGQ
Explore Nuclear receptor subfamily 2 group F member 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets